解放军医学杂志2024，Vol.49Issue(11)：1237-1243,7.DOI:10.11855/j.issn.0577-7402.0201.2024.0820
难治性催乳素瘤的临床应对:石以砥焉,化钝为利
Clinical management of refractory prolactinomas:stone to sharpen yan,blunt for profit
摘要
Abstract
Refractory prolactinoma is the most common pituitary neuroendocrine tumor.Dopamine receptor agonists(DA)are the primary choice for drug treatment.Most patients with prolactinomas respond well to DA.However,a minority of prolactinomas patients still show resistance to DA.Although drug-resistant and refractory prolactinomas are rare in clinical practice,their treatment is extremely challenging.Even a combination of drug therapy,multiple surgeries,and radiotherapy may not yield satisfactory outcomes.Therefore,standardizing the diagnosis and treatment process and pathway for refractory prolactionmas and exploring more effective multidisciplinary collaborative treatment strategies are urgent problems to be solved.In the clinical management of refractory prolactinomas,it is often necessary to consider the patient's condition comprehensively,replace other types of DA,or consider surgery,radiotherapy,and immunotherapy,which requires multidisciplinary diagnosis and treatment.This review synthesizes the latest literature at home and abroad to systematically discuss the latest advances in drug therapy,surgery,and radiotherapy treatments for refractory prolactionmas,aiming to provide new ideas for basic research,clinical diagnosis and treatment.关键词
难治性催乳素瘤/多巴胺/临床治疗Key words
refractory prolactinoma/dopamine/clinical treatment分类
医药卫生引用本文复制引用
王瑞风,马驰原,邵加庆,叶小珍,李建瑞,李静,李家亮,丛子翔,陆燕,吴楠,戈一峰..难治性催乳素瘤的临床应对:石以砥焉,化钝为利[J].解放军医学杂志,2024,49(11):1237-1243,7.基金项目
This work was supported by the National Natural Science Foundation of China(82004138) 国家自然科学基金(82004138) （82004138）
